AbilityPharma, the biopharmaceutical company and CataloniaBio & HealthTech member, has been granted with €2 million of non-dilutive funding to speed up the regulatory path for its anticancer autophagy inducer ABTL0812.

The grant, from the Proyectos de colaboración público-privada from the Ministry of Science and Innovation of the Government of Spain, covers CMC and toxicology development and boosts the clinical activities in pancreatic cancer. The Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Hospital Clinic de València (INCLIVA Instituto de Investigación Sanitaria) and Hospital Virgen del Rocio Seville (OTT- FISEVI) are part of the consortium awarded by the grant.

AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. They are focused on autophagy as a new therapeutic strategy to induce cancer cell death. Based on this novel mechanism of action, they are generating a portfolio of new drugs targeting oncological unmet needs.

Photo: AbilityPharma management team.